AVIDITY BIOSCIENCES INC (RNA)
US05370A1088 - Common Stock
Avidity Biosciences to Participate in Upcoming Investor Conference
/PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...
Avidity Biosciences, Inc. Announces Pricing of Public Offering of Common Stock
/PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...
Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock
/PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...
Notable Wednesday Option Activity: RNA, SWK, QCOM
Let's take a look at the stocks that are in motion in today's session.
Looking for insights into the US markets one hour before the close of the markets on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
These stocks are moving in today's session
Wondering how the US markets performed in the middle of the day on Wednesday? Discover the movers and shakers of today's session in our comprehensive analysis.
Wednesday's session: gap up and gap down stocks
Gap analysis on 2024-06-12: gap up and gap down stocks in today's session.
The 'Impressive' Results That Sent Top 1% Avidity Biosciences To A High Point
The company is working on a treatment for a rare form of muscular dystrophy.
Stay updated with the stocks that are on the move in today's pre-market session.
As we await the opening of the US market on Wednesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Avidity Announces Unprecedented AOC 1020 Data from Phase 1/2 FORTITUDE™ Trial Demonstrating Greater Than 50 Percent Reduction in DUX4 Regulated Genes and Trends of Functional Improvement in People Living with Facioscapulohumeral Muscular Dystrophy
Avidity plans to accelerate the initiation of registrational cohorts in FORTITUDE™ trial Delpacibart braxlosiran (AOC 1020), the first investigational therapy...
Avidity Biosciences to Present Preliminary Data from Phase 1/2 FORTITUDE™ Trial of AOC 1020 in People Living with Facioscapulohumeral Muscular Dystrophy at 31st Annual FSHD Society International Research Congress
/PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...
2 Potentially High-Reward Growth Stocks to Buy Right Now
These two biotechnology stocks could be gearing up for a run.
Dip Then Rip? 3 Nasdaq Stocks to Buy Before the Rebound
Discover three top Nasdaq stocks to buy. Learn about these investment opportunities and why they’re worth your attention.
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
/PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...
First Week of RNA July 19th Options Trading
RNA Stock Earnings: Avidity Biosciences Misses EPS, Beats Revenue for Q1 2024
RNA stock results show that Avidity Biosciences missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
RNA Stock Earnings: Avidity Biosciences Misses EPS, Beats Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Avidity Biosciences (NASDAQ:RNA) just reported results for the first quarter of...
Avidity Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
Initiation of global Phase 3 HARBOR™ trial for del-desiran (AOC 1001) in DM1 on track for this quarter Avidity to report FSHD data from FORTITUDE™ trial this...
Avidity Biosciences to Participate in Upcoming Investor Conference
/PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...
Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran (AOC 1001) for Treatment of Myotonic Dystrophy Type 1
/PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...
Interesting RNA Put And Call Options For December 20th
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
/PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...
RNA January 2025 Options Begin Trading
Avidity Biosciences to Participate in Upcoming Investor Conferences
/PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
/PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...